Results 21 to 30 of about 160,542 (279)

Pembrolizumab-induced pneumonitis with a perilymphatic nodular pattern in a lung cancer patient: A radio-pathologic correlation

Respiratory Medicine Case Reports, 2019
A 66-year-old Japanese man with recurrent adenocarcinoma of the lung p-stage IIIA (pT2bN2M0; version 8) on pembrolizumab was present with gradually worsening dyspnea.
Ryo Ueno, Masahiro Nemoto, Wataru Uegami, Junya Fukuoka, Masafumi Misawa   +4 more
doaj   +1 more source

Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study [PDF]

, 2022
BACKGROUND: We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and the pyrimidine antimetabolite gemcitabine in HER2- advanced breast cancer (ABC) patients previously treated in the advanced setting,
Soto, A., Jiménez‑Cortegana, C. (C.), Rojo, F, Casas, M. (M.), Cortés, A., Ceballos, I, Sánchez-Margalet, V. (V.), Ceballos, I., Casas, M., Gion, M, Cruz, J, Soto, A. (A.), Rodríguez, L.M. (L. M.), Cruz-Merino, L. (Luis) de la, Andrés, R, Ramos, M, Bezares, S. (S.), Cortés, A. (A.), Andrés, R., Santisteban, M. (Marta), de la Cruz-Merino, L, Rodriguez, L. M., Puertes, A. (A.), Ramos, M. (Marina), Rojo-Todo, F. (Federico), Palazón-Carrión, N., Cortes, J. (Javier), Casas, M, Chiesa, M, Holgado, E, Ceballos, I., Benito, S. (S.), Cruz-Merino, L. de la, Holgado, E. (E.), Puertes, A, Puertes, A., Quiroga, V. (V.), Caballero, R., Holgado, E., Chiesa, M. (M.), Moreno, F. (Fernando), Gion, M., de la Cruz-Merino, L., Chiesa, M., Alonso‑Romero, J.L. (J. L.), Santisteban, M., Palazón-Carrión, N, Ramos, M., Henao, F., Quiroga, V, Palazón‑Carrión, N. (N.), Gion, M. (M.), Moreno, F, Cruz, J. (J.), Henao, F. (F.), Benito, S., Ceballos, I.(I.), Rodriguez, L M, Benito, S, Bezares, S, Quiroga, V., López-Miranda, E., Cortés, J, Soto, A, Moreno, F., Cortés, A, Alonso-Romero, JL., Caballero, R, Sánchez-Margalet, V., Bezares, S., Jiménez-Cortegana, C, Alonso-Romero, José Luis, Jiménez‑Cortegana, C., López‑Miranda, E. (E.), Cruz, J., Sánchez-Margalet, V, Alonso-Romero, J L, Cortés, J., Caballero, R. (R.), López-Miranda, E, Rojo, F., Jiménez-Cortegana, C., Santisteban, M, Henao, F, Andrés, R. (R.), Sánchez‑Margalet, V.   +85 more
core   +1 more source

Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome

OncoImmunology, 2022
The PD-1 inhibitor pembrolizumab is effective in treating Sézary syndrome, a leukemic variant of cutaneous T-cell lymphoma. Our purpose was to investigate the effects of pembrolizumab on healthy and malignant T cells in Sézary syndrome and to discover ...
Tianying Su, George E. Duran, Alexa C. Kwang, Nirasha Ramchurren, Steven P. Fling, Youn H. Kim, Michael S. Khodadoust   +6 more
doaj   +1 more source

Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature

Thoracic Cancer, 2020
Several studies have demonstrated increased pericardial effusion during anti‐PD‐1 immunotherapy, and treatment in patients who have developed pericardial tamponade is controversial.
Kazuaki Harada, Makoto Ogasawara, Akane Shido, Akimitsu Meno, Soichiro Oda, Shota Yoshida, Sonoe Yoshida, Ayumu Yoshikawa, Ko Ebata, Satoshi Abiko, Naoki Kawagishi, Itsuki Sano, Hisashi Oda, Takuto Miyagishima   +13 more
doaj   +1 more source

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

, 2020
BACKGROUND Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) tumors after previous therapy.
García Carbonero, Rocío, André, Thierry, Díaz, Luis A.   +2 more
core   +1 more source

Monitoring antibody binding to T cells in a pembrolizumab‐treated patient with lung adenocarcinoma on hemodialysis

Thoracic Cancer, 2019
Recent clinical trials have demonstrated that anti‐PD‐1 blocking antibodies showed remarkable clinical efficacy in a subset of non‐small cell lung cancer (NSCLC) patients.
Akio Osa, Takeshi Uenami, Yujiro Naito, Haruhiko Hirata, Shohei Koyama, Takayuki Takimoto, Takayuki Shiroyama, Shinji Futami, Saeko Nakatsubo, Nobuhiko Sawa, Yukihiro Yano, Izumi Nagatomo, Yoshito Takeda, Masahide Mori, Hiroshi Kida, Atsushi Kumanogoh   +15 more
doaj   +1 more source

A Case of Lung Adenocarcinoma with Long-Term Response after Late-Onset Pembrolizumab-Induced Acute Adrenal Insufficiency

Case Reports in Oncology, 2021
Pembrolizumab is an anti-programmed cell death protein-1 antibody that is mainly used for the treatment of non-small cell lung cancer (NSCLC). Immune-related adverse events can be caused by immune checkpoint inhibitors; however, few case reports evaluate
Kei Sonehara, Kazunari Tateishi, Taro Hirabayashi, Taisuke Araki, Yuichi Ikuyama, Ryosuke Machida, Masayuki Hanaoka   +6 more
doaj   +1 more source

Pembrolizumab: review of its current therapeutic uses

, 2023
Background: Pembrolizumab is a humanized monoclonal antibody approved for human use in 2014 by the Food and Drug Administration (FDA) and in 2015 by the European Medicines Agency (EMA).
Silva, Rui, Fonseca, Sílvia, Oliveira, Susana   +2 more
core   +1 more source

Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study

Cancer Medicine, 2023
Background The phase 3 CLEAR study demonstrated statistically significantly improved efficacy with lenvatinib plus pembrolizumab versus sunitinib, including progression‐free survival and overall survival, in patients with previously untreated advanced ...
Masatoshi Eto, Toshio Takagi, Go Kimura, Satoshi Fukasawa, Satoshi Tamada, Yuji Miura, Mototsugu Oya, Naoto Sassa, Satoshi Anai, Masahiro Nozawa, Hideki Sakai, Rodolfo Perini, Wataru Yusa, Hiroki Ikezawa, Tomoyuki Narita, Yoshihiko Tomita   +15 more
doaj   +1 more source

Pembrolizumab Associated Autoimmune Diabetes Mellitus: Case Series [PDF]

The use of immune checkpoint inhibitors is increasing every day. With such frequent use, the side effects and management associated with these treatments are becoming difficult. One of rare side effects is autoimmune diabetes mellitus. In this review, we
Aslı GEÇGEL, Erhan GÖKMEN, Oğuzcan ÖZKAN   +2 more
core   +1 more source